Received Feb 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 47XE4 | — |
administration of Pediatric dose of Engerix B to adult patient.; administering a pediatric dose of Engerix B to an adult patient; This non-serious case was reported by a other health professional via call center representative and described the occurrence of adult use of a child product in a 37-year-old male patient who received HBV (Engerix B pediatric) (batch number 47XE4, expiry date 16-JUL-2026) for prophylaxis. On 19-FEB-2025, the patient received Engerix B pediatric. On 19-FEB-2025, an unknown time after receiving Engerix B pediatric, the patient experienced adult use of a child product (Verbatim: administration of Pediatric dose of Engerix B to adult patient.) and underdose (Verbatim: administering a pediatric dose of Engerix B to an adult patient). The outcome of the adult use of a child product and underdose were unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date :19-FEB-2025 Medical assistant called to request information on how to proceed after administering a pediatric dose of Engerix B to an adult patient that is still in the office. Then reporter reported administered to a pediatric dose of Engerix B to an adult patient, which led to underdose and adult use of a child product. The reporter consented to follow up. The Vaccine Administration Facility is the same as Primary Reporter.